Matrixyl

Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS)

1. Basic Overview

Matrixyl, chemical name Palmitoyl Pentapeptide-4 (Pal-KTTKS), is a synthetic lipophilic signal peptide developed by Sederma.

• Amino Acid Sequence: Palmitoyl-Lys-Thr-Thr-Lys-Ser
• CAS Number: 214047-00-4
• Molecular Weight: 802.05 Da
• Form: Lyophilized white crystalline powder
• Core feature: The palmitoyl fatty acid chain improves skin penetration. It acts as a matrikine to stimulate fibroblasts to rebuild dermal extracellular matrix.

2. Mechanism of Action

1. Mimics natural collagen breakdown fragments (matrikine signaling). It signals dermal fibroblasts to initiate tissue remodeling response.
2. Upregulates TGF-β pathway, significantly boosting synthesis of Collagen I, III, IV, fibronectin and glycosaminoglycans.
3. Balances matrix metalloproteinase (MMP) activity to slow excessive collagen degradation.
4. Enhances epidermal-dermal junction integrity, improves skin thickness and reduces fine wrinkle formation.
5. Supports angiogenesis and accelerates mild wound healing in epithelial tissue models.

3. Main Research Applications

• Skin aging, wrinkle formation and dermal thinning research
• Fibroblast extracellular matrix synthesis in vitro experiments
• Topical peptide penetration & lipopeptide delivery system studies
• Skin barrier repair and anti-photoaging models
• Comparative research: Matrixyl vs GHK-Cu, Argireline, and other cosmetic peptides
• Formulation development for anti-aging serum & cream prototypes
• Combined peptide research with hyaluronic acid, vitamin C and retinoids

4. Reconstitution Instructions (Lyophilized Vial)

Common specification: 5mg / 10mg per vial

1. Allow vial to reach room temperature; disinfect rubber stopper with alcohol wipe.
2. Slowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.

3. Gently rotate the vial to dissolve powder. DO NOT shake violently to prevent peptide aggregation. Qualified solution is clear and colourless.
4. Storage Requirements

• Unreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.
• Reconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days. Do not freeze reconstituted liquid.

5. Research Administration Protocols

Topical Application (Main Experimental Method)

• Working concentration for in vivo skin research: 0.5mg/mL – 2.5mg/mL
• Application frequency: Once or twice daily
• Operation: Apply evenly to target skin region; gently massage for absorption. Allow full penetration before overlaying other agents.
• Reference experimental cycle: Continuous treatment for 8–12 weeks to observe ECM remodeling changes.

Subcutaneous Injection (Only for specialized animal research)

• Reference experimental dosage: 200–500 mcg, once daily
• Injection site: Localized subcutaneous tissue near experimental skin lesion
• Cycle: Max 6 weeks continuous administration; pause 4 weeks before new research cycle.

6. Precautions & Observed Adverse Reactions

1. Pure laboratory research compound. Not authorized for human therapeutic injection.
2. Strict aseptic technique required during reconstitution to prevent microbial contamination.
3. Discard solution immediately if turbidity, precipitation or discoloration appears.
4. Observed mild reactions: occasional transient local redness or slight irritation in sensitive tissue models. Systemic side effects are extremely rare.
5. Matrixyl is lipophilic; avoid mixing with strongly acidic or alkaline solutions to prevent structural degradation.
6. Not interchangeable with Matrixyl 3000 or Synthe’6; peptide composition and activity spectrum differ.

Short Version (For Product Page / Customer Direct Message)

Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS)

Matrixyl is a lipophilic synthetic signal peptide (matrikine). It stimulates dermal fibroblasts to produce collagen, fibronectin and other extracellular matrix components. Widely used in laboratory research focusing on skin anti-aging, wrinkle improvement, epidermal repair and cosmetic peptide formulation testing.

Reconstitution

Mix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.

Reference Research Administration

Topical: 0.5–2.5 mg/mL solution, 1–2 times daily for 8–12 weeks. Subcutaneous injection (animal research only): 200–500 mcg once daily.